Hepatitis is one of the world’s top ten deadly diseases and has become a serious global health concern. Currently, about 2 billion people worldwide are infected with hepatitis.

Laos’s pharmaceutical industry is not highly developed, and its scale is far smaller than that of India or Bangladesh. The country’s geographical disadvantage is also obvious: as a landlocked nation without seaports and with a small population and labor shortage, manufacturing is constrained. Yet this disadvantage is also an advantage—with few independent national standards of its own, the pharmaceutical industry directly adopts U.S. FDA standards. Adopting U.S. standards directly means Laos’s pharmaceutical sector gains easier access to international markets.

Lucius Pharmaceutical was founded in 2014, originating from Hyderabad, India’s pharmaceutical hub. Laos has complete legal treaties and policies governing generic drug manufacturing, and the construction of its Lao factory received strong support from the local government. Moreover, Laos’s pharmaceutical industry enjoys convenient access to international markets.

Lucius Pharmaceutical (Laos) Co., Ltd. is one of the major Lao pharmaceutical enterprises producing the latest treatments for hepatitis C and B, providing affordable, high-quality new drug regimens for hepatitis patients worldwide. After achieving major breakthroughs in the production and R&D of anti-cancer drugs, Lucius is now manufacturing and supplying the latest hepatitis therapies. Lucius has successively launched the world’s first generic versions of Tenofovir Alafenamide (TAF) and Epclusa (Sofosbuvir and Velpatasvir), allowing HCV patients around the world to obtain new hepatitis C treatments at less than one percent of the originator drug’s price.